Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 2, 2010, Pages 210-220

  Shimano, Masayuki ^a,c   Ouchi, Noriyuki ^a   Shibata, Rei ^c   Ohashi, Koji ^a   Pimentel, David R ^b   Murohara, Toyoaki ^c   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Myocardial Biology Unit   (United States)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; AMPK; Cardiac angiogenesis; Heart failure; Pressure overload

Indexed keywords

ADENOVIRUS VECTOR; ADIPOCYTOKINE; ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INHIBITION; HEART DEVELOPMENT; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; KNOCKOUT MOUSE; LUNG CONGESTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC DYSFUNCTION; WILD TYPE;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CAPILLARIES; CARDIOMEGALY; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; HEART; HEART FAILURE; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PRESSURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR REMODELING;

ADENOVIRIDAE; MUS;

EID: 77953691004     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.02.021     Document Type: Article

References (47)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiography determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 1990, 322:1561-1566.
2. Frey N., Katus H.A., Olson E.N., Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 2004, 109:1580-1589.
3. Luedde M., Katus H.A., Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Pat. Cardiovasc. Drug Discov. 2006, 1:1-20.
4. Izumiya Y., Shiojima I., Sato K., Sawyer D.B., Colucci W.S., Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006, 47:887-893.
5. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005, 115:2108-2118.
6. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta 2007, 380:24-30.
7. Pajvani U.B., Scherer P.E. Adiponectin: systemic contributor to insulin sensitivity. Curr. Diab. Rep. 2003, 3:207-213.
8. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
9. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1595-1599.
10. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23:85-89.
11. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
12. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
13. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat. Clin. Pract. Cardiovasc. Med. 2009, 6:27-35.
14. Ouchi N., Shibata R., Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc. Med. 2006, 16:141-146.
15. Duda M.K., O'Shea K.M., Lei B., Barrows B.R., Azimzadeh A.M., McElfresh T.E., et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc. Res. 2007, 76:303-310.
16. Shibata R., Izumiya Y., Sato K., Papanicolaou K., Kihara S., Colucci W.S., et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol. 2007, 42:1065-1074.
17. Shibata R., Sato K., Kumada M., Izumiya Y., Sonoda M., Kihara S., et al. Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc. Res. 2007, 74:471-479.
18. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
19. Tao L., Gao E., Jiao X., Yuan Y., Li S., Christopher T.A., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007, 115:1408-1416.
20. Wang Y., Gao E., Tao L., Lau W.B., Yuan Y., Goldstein B.J., et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844.
21. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005, 67:705-713.
22. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 2004, 10:1384-1389.
23. Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y., et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 2004, 94:e27-e31.
24. Li R., Wang W.Q., Zhang H., Yang X., Fan Q., Christopher T.A., et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1703-E1708.
25. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 2002, 277:37487-37491.
26. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem. 2004, 279:1304-1309.
27. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem. 2004, 279:28670-28674.
28. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8:731-737.
29. Kondo M., Shibata R., Miura R., Shimano M., Kondo K., Li P., et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J. Biol. Chem. 2009, 284:1718-1724.
30. Takahashi A., Kureishi Y., Yang J., Luo Z., Guo K., Mukhopadhyay D., et al. Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth. Mol. Cell. Biol. 2002, 22:4803-4814.
31. Pimentel D.R., Amin J.K., Xiao L., Miller T., Viereck J., Oliver-Krasinski J., et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 2001, 89:453-460.
32. Kondo K., Shintani S., Shibata R., Murakami H., Murakami R., Imaizumi M., et al. Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:61-66.
33. Ouchi N., Shibata R., Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ. Res. 2005, 96:838-846.
34. Chen M.B., McAinch A.J., Macaulay S.L., Castelli L.A., O'Brien P.E., Dixon J.B., et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab. 2005, 90:3665-3672.
35. Fujioka D., Kawabata K., Saito Y., Kobayashi T., Nakamura T., Kodama Y., et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2409-H2416.
36. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006, 116:1784-1792.
37. Ohashi K., Ouchi N., Sato K., Higuchi A., Ishikawa T.O., Herschman H.R., et al. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol. Cell. Biol. 2009, 29:3487-3499.
38. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kaneko K., Okazaki Y., et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem. Biophys. Res. Commun. 2009, 382:51-56.
39. Ikeda Y, Sato K, Pimentel DR, Sam F, Shaw RJ, Dyck JR, Walsh K Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem 2009, 284:35839-35849.
40. Lee M., Hwang J.T., Lee H.J., Jung S.N., Kang I., Chi S.G., et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J. Biol. Chem. 2003, 278:39653-39661.
41. Yun H., Lee M., Kim S.S., Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J. Biol. Chem. 2005, 280:9963-9972.
42. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
43. Izumi Y., Shiota M., Kusakabe H., Hikita Y., Nakao T., Nakamura Y., et al. Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens. Res. 2009, 32:675-679.
44. Li X., Han Y., Pang W., Li C., Xie X., Shyy J.Y., et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1789-1795.
45. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005, 280:20493-20502.
46. Emerling B.M., Viollet B., Tormos K.V., Chandel N.S. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett. 2007, 581:5727-5731.
47. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.